THOUSAND OAKS, Calif.,
Feb. 22, 2021 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) will host a webcast call for the investment community
in conjunction with the 2021 American Academy of Allergy, Asthma
& Immunology (AAAAI) Annual Meeting on Friday, Feb. 26, at 1:00
p.m. ET. David M. Reese,
M.D., executive vice president of Research and Development at
Amgen, along with clinical trial investigators, will discuss the
results of the tezepelumab Phase 3 NAVIGATOR study in patients with
severe asthma.
Live audio of the conference call will be broadcast over the
internet simultaneously and will be available to members of the
news media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given at certain investor and
medical conferences, can be accessed on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the event.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has
reached millions of patients around the world and is developing a
pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Trish Rowland,
805-447-5631(media)
Arvind Sood, 805-447-1060
(investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-meeting-at-aaaai-virtual-annual-meeting-301232764.html
SOURCE Amgen